Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Pfizer Seeks More M&A to Expand China Generic Drug Offerings

publication date: Feb 22, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer wants to keep pursuing “opportunities” in China and India to expand its portfolio of generic drugs. The company made the declaration soon after announcing a $545 million generic JV deal with Zhejiang Hisun Pharma. According to an unnamed Pfizer spokesperson who spoke to Reuters, Pfizer is open to business development deals of all types, including partnerships, with China and Indian pharmas to help Pfizer attain this goal. More details....

Stock Symbols: (NYSE: PFE) (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors